We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A majority of physicians have some kind of relationship with the pharmaceutical industry, such as receiving gifts of food and drug samples, despite efforts to regulate such interactions, a new study reported. Read More
PhRMA voiced opposition to proposed legislation that would create a pathway for the FDA to approve follow-on biologics because it will not ensure patient safety and will hinder innovation, the group said.
Drugmakers spent $155 million lobbying Congress between January 2005 and June 2006, trying to influence legislation on Medicare, drug importation and patent protection, according to a study by The Center for Public Integrity.
Drugmakers spent $155 million lobbying Congress between January 2005 and June 2006, trying to influence legislation on Medicare, drug importation and patent protection, according to a study by The Center for Public Integrity.
Both chambers of Congress passed legislation providing funding for biodefense programs and reauthorizing the NIH after a last-minute deal between Senate negotiators and Rep. Joe Barton (R-Texas), an industry source says.
The Senate’s approval of an amendment allowing for the importation of drugs from Canada undermines both government border control and the safety and efficacy of the U.S. drug supply, an industry group says.
PhRMA is opposing the World Health Organization’s (WHO) plan to register every clinical trial conducted anywhere in the world, arguing this could have a chilling effect on new drug
development.
Pharma manufacturers must make sure their IT systems can provide a record of the gifts their sales reps have made to physicians in seven states and the District of Columbia, and the other 43 states are likely to follow suit within 12 to 18 months, according to a new study by the technology research firm Gartner.
The FTC’s pledge to challenge the constitutionality of brand name drug companies’ strategy of paying generic manufacturers to drop patent-infringement suits is likely to fail, PhRMA President Billy Tauzin told WDL.